Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases
摘要:
Novel bone-targeted 2,6,9-trisubstituted purine template-based inhibitors of Src tyrosine kinase are described. Drug design studies of known purine compounds revealed that both positions-2 and -6 were suitable for incorporating bone-seeking moieties. A variety of bone-targeting groups with different affinity to hydroxyapatite were utilized in the study. Compound 3d was determined to be a potent Src inhibitor and was quite selective against a panel of other protein kinases. (C) 2003 Elsevier Ltd. All rights reserved.
This invention relates to compounds of the general formula:
1
in which R
A
, R
B
, R
C
and R
D
are as defined herein, and to their preparation and use.
本发明涉及一般式为1的化合物,其中RA、RB、RC和RD的定义如本文所述,以及它们的制备和使用。
[EN] PURINE DERIVATIVES<br/>[FR] DERIVES DE LA PURINE
申请人:ARIAD PHARMA INC
公开号:WO2001044259A1
公开(公告)日:2001-06-21
This invention relates to compounds of general formula (I) in which R?A, RB, RC and RD¿ are as defined herein, and to their preparation and use.
本发明涉及一般式(I)的化合物,其中R?A,RB,RC和RD¿如本文所定义,以及它们的制备和使用。
Novel perines
申请人:Metcalf A. Chester
公开号:US20050096298A1
公开(公告)日:2005-05-05
Novel purines and uses of these compounds for the treatment of bone related disorders and cancer is disclosed.
本发明揭示了新型嘌呤类化合物及其用于治疗与骨相关的疾病和癌症的用途。
Novel purinse
申请人:——
公开号:US20020132819A1
公开(公告)日:2002-09-19
Novel purines and uses of these compounds for the treatment of bone related disorders and cancer is disclosed.